Day of reckoning ahead for pay-for-delay deals?
A political consensus seems to be emerging in the Senate Antitrust Subcommittee that negotiated settlements between the makers of brand-name drugs and generics to delay entry into the market are hurting...To view the full article, register now.
Already a subscriber? Click here to view full article